Drugs / AXN-2510
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07159828 | Sep 2025 → Apr 2026 | cancer | Axion Bio, Inc | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-09-10 | Instil Bio | Results Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC) instilbio.com ↗
ImmuneOnco reported that 23 patients with sq-NSCLC had been treated with monotherapy ‘2510 as of June 13, 2025. |
| 2025-07-31 | Instil Bio | Results ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China instilbio.com ↗
Partial responses were observed in 62% of efficacy evaluable patients, comprising partial responses in 80% (8/10) of patients with squamous NSCLC and 46% (5/11) of patients with non-squamous NSCLC. |
| 2025-07-02 | Instil Bio | Regulatory Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors instilbio.com ↗
Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the clearance of an Investigational New Drug (IND) application for AXN-2510 (“’2510”) by the U.S. Food and Drug Administration. |
| 2025-05-22 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Results 宜明昂科宣布IMM2510联合化疗治疗一线NSCLC的II期临床将于2025年三季度完成入组；初步数据预计将在今年下半年公布 immuneonco.com ↗
显示出23%的客观缓解率(可评估疗效的患者数为13)。 |
All press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AXN-2510 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07159828 ↗ |
| Action | Inhibit | “PD-L1 blocking and VEGF inhibition activity” NCT07159828 ↗ |
| Route | Intravenous | “AXN-2510 given as intravenous (IV) infusion” NCT07159828 ↗ |